FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to a pharmaceutical dosage form with sustained release of tofacitinib for administration once a day. Dosage form contains a core comprising 11 mg of tofacitinib or an equivalent amount of tofacitinib in the form of its pharmaceutically acceptable salt and osmagen, and a semi-permeable membrane coating surrounding the core, where said coating contains a water-insoluble polymer. Water-insoluble polymer is a derivative of cellulose, in particular cellulose acetate. Osmagen contains sugar, where the sugar is sorbitol.
EFFECT: pharmaceutical dosage forms of the invention are characterised by relatively short sustained release periods and longer rest periods from tofacitinib medication.
25 cl, 49 tbl, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ORAL DOSAGE FORMS OF TOFACITINIB WITH CONTINUOUS RELEASE | 2014 |
|
RU2790166C2 |
| METHODS AND MEDICINAL FORMULATIONS FOR CONTROLLED DELIVERY OF PALIPERIDONE | 2003 |
|
RU2321391C2 |
| DOSAGE FORMS WITH RETARDED RELEASE OF ZIPRASIDONE | 2004 |
|
RU2351316C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING DIACEREIN | 2009 |
|
RU2542461C2 |
| CONTROLLED-RELEASE HYDROCODON COMPOSITION | 2001 |
|
RU2253452C2 |
| FORM OF PROLONGED VENLAFAXINE HYDROCHLORIDE LIBERATION | 2004 |
|
RU2340331C2 |
| MODIFIED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING FEBUXOSTAT | 2011 |
|
RU2602188C2 |
| MEDICINAL CONTROLLED-RELEASING FORMS OF AZITHROMYCIN | 1995 |
|
RU2130311C1 |
| SOLID PHARMACEUTICAL PREPARATIONS CONTAINING PHYSICAL MIXTURE OF CYCLODEXTRIN SULFOALKYL ETHER AND THERAPEUTIC AGENT | 1998 |
|
RU2173172C2 |
| PHARMACEUTICAL COMPOSITION IN FORM OF SINGLE ORAL DOSE CONTAINING LEVODOPA, CARBIDOPA AND ENTACAPONE, OR SALTS THEREOF | 2009 |
|
RU2519159C2 |
